The global, full-service CRO that does the unglamorous, exacting work of turning molecules into approved medicine.
The logo of a company most patients will never hear of, attached to drugs many of them will one day take. Horsham, Pennsylvania.
Not literally. ClinChoice rarely is. The company works in the wings - protocols, monitoring visits, statistical plans, safety reports, regulatory filings. The slow machinery between a promising compound and a prescription. It is precise, it is heavily documented, and it is almost entirely invisible to the patient who eventually benefits from it.
Today ClinChoice is a mid-size global contract research organization with roughly 4,000 people spread across the Americas, Europe, and Asia-Pacific. It runs clinical development for pharmaceutical, biotech, medical device, and consumer health companies - six of the top ten drugmakers among them, and a long roster of biotechs you have not heard of yet. It is the kind of firm that measures its life in submissions filed and studies delivered, not headlines.
Four numbers that explain a company. None of them fit on a billboard, which is rather the point.
A new medicine can take a decade and a fortune to reach approval, and most candidates fail somewhere along the way. The science is hard. The regulations are unforgiving. And the smaller the company sponsoring the trial, the less likely it is to have a global clinical operations team sitting in-house. This is the gap ClinChoice was built to stand in.
The pitch is unsentimental: hand the trial, or a piece of it, to people who run trials for a living. Sponsors get clinical operations, biometrics, safety, regulatory affairs, and medical writing without building all of it themselves. The promise is quality, speed, and access - the three things every drug program is short on at once.
More than 60% of ClinChoice's clients are emerging and mid-size biotechs - the companies for whom a single program is often the whole company. For them, a CRO is not a vendor. It is the difference between a trial that reads out and one that quietly runs out of runway.
ClinChoice traces back to 1995 and to founders Xin Ke and John D. Balian - the latter a former senior executive across Johnson & Johnson, Pfizer, and Bristol-Myers Squibb, where he worked on regulatory affairs, clinical research, and safety. For most of its life the company operated as Fountain Medical Development, known in the industry as FMD K&L, methodically building presence across North America, Asia, and Europe.
The bet was geography. A drug approved in one market still has to clear the next, and sponsors increasingly run trials on several continents at once. ClinChoice wagered that a CRO combining global reach with deep local know-how would matter more over time, not less. Then, in 2020, it did the most consequential thing a 25-year-old company can do: it changed its name.
The rebrand unified a patchwork of affiliates under one banner. Two years later, the capital followed.
Xin Ke and John D. Balian launch the clinical CRO that would spend decades building a quiet global footprint.
Operations expand across North America, Asia, and Europe; 3,000+ studies delivered from 2010 onward.
FMD K&L and its affiliates consolidate under a single name and identity: ClinChoice Inc.
A round led by Legend Capital, with Lilly Asia Ventures, Apricot Capital, Taikang, and Sherpa, funds acquisitions and global expansion.
The Italy- and US-based full-service CRO joins ClinChoice, deepening its European and North American reach.
ClinChoice highlights completion of the deal, extending its global service network further still.
A timeline with no zigzags. That is unusual for a CRO, and ClinChoice would like you to notice.
ClinChoice sells the full arc of clinical development, and lets sponsors decide how much of it to hand over. Take the whole program on a full-service basis, or embed ClinChoice staff into your own team through a functional-service-provider model. The menu is wide because the customers' needs are not the same on any two days.
Study start-up, monitoring, medical monitoring, and trial management across all phases.
Biostatistics, data management, statistical programming, and data science behind the numbers.
Drug safety and product vigilance across the full product lifecycle.
Regulatory strategy, submissions, and scientific writing - 10,000+ filings deep.
Late-phase, observational, and real-world evidence studies for marketed products.
Flexible embedded resourcing plus eClinical systems, data visualization, and consulting.
Six services that sound like an HR org chart and function like a pit crew.
The therapeutic focus is where the science is hardest: oncology, inflammation and immunology, cardiometabolic disease, and the central nervous system - areas where trials are long, endpoints are stubborn, and the margin for sloppiness is zero.
In July 2022, ClinChoice raised a $150 million Series E led by Legend Capital, joined by Taikang Life Insurance, Sherpa Healthcare Partners, and existing backers Lilly Asia Ventures and Apricot Capital. The stated plan was blunt: fund growth through acquisitions and internal expansion. The CROMSOURCE deal that followed was that plan, made visible.
Relative scale of ClinChoice's track record. Bars are scaled for comparison, not drawn to a single axis.
The customer mix tells its own story. Six of the world's ten largest pharmaceutical companies on one end; a majority of clients from emerging and mid-size biotech on the other. ClinChoice sits between the giants and the upstarts, useful to both for opposite reasons.
Strip away the corporate language and ClinChoice's mission is straightforward: get good drugs and devices to people faster, without cutting the corners that keep them safe. It is the contradiction at the heart of the whole industry, and ClinChoice has chosen to live inside it rather than pick a side.
That is why the company keeps emphasizing three words - quality, speed, and access. Quality, because regulators and patients both pay for mistakes. Speed, because every month a therapy is delayed is a month patients wait. Access, because a trial that only runs in a few wealthy markets is not really global at all.
More candidates are entering development from smaller companies than ever, and those companies cannot run global trials alone. As long as that is true, the firms that can run trials well - on three continents, across the hardest diseases, with the paperwork to prove it - will be quietly indispensable. ClinChoice is betting it will be one of them.
Its strategy from here is the same one it has run for thirty years, only faster: expand the footprint, deepen the science, fold in acquisitions like CROMSOURCE, and keep the trains running on the unglamorous schedule that drug approval demands.
The form is signed, the data starts flowing, and a statistician somewhere already knows what the analysis plan will look like. None of it carries ClinChoice's name where the patient can see it. That is fine. The company never built itself to be seen. It built itself to be the reason a trial reads out on time, a submission clears, and a medicine that did not exist last decade becomes ordinary.
Thirty years in, the work has not changed. The scale has. And the next first patient, in the next room, is already waiting.
Website, social profiles, the funding announcement, and the CROMSOURCE acquisition news - everything cited in this profile.